Novartis strengthens executive committee further
Novartis this week announced changes to its senior leadership team to support the implementation of its strategic priorities. These changes include the appointment of Shannon Klinger in the elevated and expanded role of chief ethics, risk, and compliance officer, effective April 1.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
OpinionExperts outline core skills compliance teams need to develop in 2026
Compliance teams will face a range of ongoing challenges in the coming year, as well as greater demands from boards and management for better, wider, and more real-time assurance on an increasing range of risk topics.
-
OpinionHow to identify and mitigate risks posed by Foreign Terrorist Organizations
Since Inauguration Day on Jan. 20, 2025, the Trump Administration has made it a priority to expand the list of designated Foreign Terrorist Organizations.